Condition: Respiratory Syncytial Virus (RSV) · Influenza A(H5N1) · Sponsor: Sanofi
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to 49 years. The total duration of study participation for each participant varies by stage and treatment arm. Stage 1: * For Arm 1, Arm 2, and Arm 3 the duration of study participation will be approximately 7 months for each participant. * For Arm 4, Arm 5, and Arm 6 the duration of study participation will be approximately 6 months for each participant. Stage 2: For all arms, the duration of study participation will be approximately 7 months for each participant.
This description comes directly from the study's public registry record.
Sanofi Trial Transparency Email Recommended (Toll free for US and Canada) · 800-633-1610 · contact-us@sanofi.com
Always discuss trial participation with your own doctor first.
| Site # 0361002 | Griffith, Queensland, Australia | Recruiting |
| Site # 0361001 | Herston, Queensland, Australia | Recruiting |
| Site # 0361003 | Morayfield, Queensland, Australia | Recruiting |
| Site # 0361005 | Sippy Downs, Queensland, Australia | Recruiting |
| Site # 03610004 | South Brisbane, Queensland, Australia | Recruiting |
| Site # 036006 | Taringa, Queensland, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07516418